{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:06Z","timestamp":1791925746875,"version":"4.3.4"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss. The main pathological features are neuronal fibrillary tangles caused by amyloid beta deposition and hyperphosphorylation of tau protein, accompanied by neuronal death and loss of synaptic structure. Early diagnosis is the key to the treatment of AD. It is known that some small molecular components are related to the pathogenesis of AD. This article will summarize the common AD biomarkers in cerebrospinal fluid and blood and analyze the current status of AD biomarkers and future research directions. This review summarizes the promising biomarkers for the diagnosis of AD in the last decade and describes their changes in AD body fluids. The diagnostic biomarkers related to AD were mainly distributed in cerebrospinal fluid and blood. Significant changes in these molecules can be detected in cerebrospinal fluid and blood, and they are correlated with AD severity. These humoral molecules have necessary relationship with AD and can be used as AD biomarkers to assist early diagnosis of AD.<\/jats:p>","DOI":"10.1097\/md.0000000000038978","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:16:29Z","timestamp":1722003389000},"page":"e38978","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Research progress on humoral biomarkers of Alzheimer\u2019s disease: A review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6733-0093","authenticated-orcid":false,"given":"Hao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Binzhou Medical College, Binzhou, China"},{"name":"Binzhou Medical College, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Binzhou Medical College, Binzhou, China"},{"name":"Binzhou Medical College, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Binzhou Medical College, Binzhou, China"},{"name":"Binzhou Medical College, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Binzhou Medical College, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ultrasound Medicine, Affiliated Hospital of Binzhou Medical College, Binzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Binzhou Medical College, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"5550938","DOI":"10.1155\/2021\/5550938","article-title":"The potential benefits of nanotechnology in treating Alzheimer\u2019s disease.","volume":"2021","author":"Ling","year":"2021","journal-title":"Biomed Res Int"},{"key":"R2-20250716","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1874609814666210302085232","article-title":"Alzheimer\u2019s disease: pathogenesis and therapeutic interventions.","volume":"15","author":"Ogbodo","year":"2022","journal-title":"Curr Aging Sci"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-201248","article-title":"The role of microglia in sporadic Alzheimer\u2019s disease.","volume":"79","author":"Streit","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"R4-20250716","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/brain\/awaa395","article-title":"Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"R5-20250716","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WCO.0000000000000788","article-title":"Current opinion neurology: visual pathway biomarkers in Alzheimer\u2019s disease.","volume":"33","author":"Van Stavern","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"R6-20250716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1567202616666190208094159","article-title":"MicroRNAs for the treatment of dementia and Alzheimer\u2019s disease.","volume":"16","author":"Maiese","year":"2019","journal-title":"Curr Neurovasc Res"},{"key":"R7-20250716","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference.","volume":"9","author":"Young","year":"2018","journal-title":"Nat Commun"},{"key":"R8-20250716","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21507740.2021.1941411","article-title":"Personal utility and early intervention in Alzheimer\u2019s disease.","volume":"12","author":"Tyler","year":"2021","journal-title":"AJOB Neurosci"},{"key":"R9-20250716","doi-asserted-by":"crossref","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","article-title":"Lecanemab demonstrates highly selective binding to Abeta protofibrils isolated from Alzheimer\u2019s disease brains.","volume":"130","author":"Johannesson","year":"2024","journal-title":"Mol Cell Neurosci"},{"key":"R10-20250716","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future.","volume":"284","author":"Blennow","year":"2018","journal-title":"J Intern Med"},{"key":"R11-20250716","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography.","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"R12-20250716","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-017-0108-5","article-title":"Re-evaluation of soluble APP-alpha and APP-beta in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders.","volume":"5","author":"Araki","year":"2017","journal-title":"Biomark Res"},{"key":"R13-20250716","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jnc.15909","article-title":"Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies.","volume":"166","author":"Wang","year":"2023","journal-title":"J Neurochem"},{"key":"R14-20250716","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s disease: mechanisms and therapeutic strategies.","volume":"15","author":"Gao","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"R15-20250716","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1073858418775027","article-title":"Fluid dynamics inside the brain barrier: current concept of interstitial flow, glymphatic flow, and cerebrospinal fluid circulation in the brain.","volume":"25","author":"Nakada","year":"2019","journal-title":"Neuroscientist"},{"key":"R16-20250716","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-981-32-9358-8_29","article-title":"Cerebrospinal fluid and plasma tau as a biomarker for brain tauopathy.","volume":"1184","author":"Shoji","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"R17-20250716","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R18-20250716","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/jnc.15252","article-title":"Molecular forms of neurogranin in cerebrospinal fluid.","volume":"157","author":"Nazir","year":"2021","journal-title":"J Neurochem"},{"key":"R19-20250716","doi-asserted-by":"crossref","first-page":"584743","DOI":"10.3389\/fnagi.2020.584743","article-title":"Neurogranin: a potential biomarker of neurological and mental diseases.","volume":"12","author":"Xiang","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"R20-20250716","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jnc.14594","article-title":"Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases.","volume":"151","author":"Brinkmalm","year":"2019","journal-title":"J Neurochem"},{"key":"R21-20250716","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/labmed\/lmaa062","article-title":"Neurogranin as a novel biomarker in Alzheimer\u2019s disease.","volume":"52","author":"Agnello","year":"2021","journal-title":"Lab Med"},{"key":"R22-20250716","first-page":"2","article-title":"Neurogranin as a reliable biomarker for synaptic dysfunction in Alzheimer\u2019s disease.","volume":"11","author":"Agnello","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R23-20250716","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40520-019-01326-z","article-title":"A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer\u2019s disease and mild cognitive impairment.","volume":"32","author":"Mavroudis","year":"2020","journal-title":"Aging Clin Exp Res"},{"key":"R24-20250716","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"alpha-synuclein in the pathophysiology of Alzheimer\u2019s disease.","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol Neurodegener"},{"key":"R25-20250716","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases.","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/medicina57090954","article-title":"Relation between alpha-synuclein and core CSF biomarkers of Alzheimer\u2019s disease.","volume":"57","author":"Monge-Garcia","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R27-20250716","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.neuron.2023.02.033","article-title":"Neuronal identity defines alpha-synuclein and tau toxicity.","volume":"111","author":"Praschberger","year":"2023","journal-title":"Neuron"},{"key":"R28-20250716","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC.","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease.","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R30-20250716","first-page":"1","article-title":"Inactivation of GAP-43 due to the depletion of cellular calcium by the Pb and amyloid peptide induced toxicity: an in vitro approach.","volume":"316","author":"Neelima","year":"2020","journal-title":"Chem Biol Interact"},{"key":"R31-20250716","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology.","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimers Dement"},{"key":"R32-20250716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aax3519","article-title":"Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer\u2019s disease pathogenesis.","volume":"12","author":"Lananna","year":"2020","journal-title":"Sci Transl Med"},{"key":"R33-20250716","first-page":"10502","article-title":"YKL-40 as a biomarker in various inflammatory diseases: a review.","volume":"34","author":"Blazevic","year":"2024","journal-title":"Biochem Med (Zagreb)"},{"key":"R34-20250716","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/medicina58010060","article-title":"YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer\u2019s disease.","volume":"58","author":"Mavroudis","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R35-20250716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau2291","article-title":"The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer\u2019s disease risk.","volume":"11","author":"Deming","year":"2019","journal-title":"Sci Transl Med"},{"key":"R36-20250716","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: current evidence and future perspectives.","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci"},{"key":"R37-20250716","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12974-020-01878-2","article-title":"TREM2 ectodomain and its soluble form in Alzheimer\u2019s disease.","volume":"17","author":"Yang","year":"2020","journal-title":"J Neuroinflammation"},{"key":"R38-20250716","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","article-title":"Astrocytosis precedes amyloid plaque deposition in Alzheimer APPs we transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.","volume":"42","author":"RodriguezVieitez","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R39-20250716","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/biom13040692","article-title":"Large-scale integration of single-cell RNA-Seq data reveals astrocyte diversity and transcriptomic modules across six central nervous system disorders.","volume":"13","author":"Qian","year":"2023","journal-title":"Biomolecules"},{"key":"R40-20250716","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.neuron.2022.03.008","article-title":"Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer\u2019s disease.","volume":"110","author":"Sadick","year":"2022","journal-title":"Neuron"},{"key":"R41-20250716","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","article-title":"Astrocyte biomarkers in Alzheimer\u2019s disease.","volume":"25","author":"Carter","year":"2019","journal-title":"Trends Mol Med"},{"key":"R42-20250716","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2174\/1567205018666211117100342","article-title":"Diversity and regulation of astrocyte neurotoxicity in Alzheimer\u2019s disease.","volume":"18","author":"Hashioka","year":"2021","journal-title":"Curr Alzheimer Res"},{"key":"R43-20250716","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1570159X15666170720095240","article-title":"Microglia and astrocytes in Alzheimer\u2019s disease: implications for therapy.","volume":"16","author":"Fakhoury","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"R44-20250716","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jalz.2019.06.4952","article-title":"Differential expression of microRNAs in Alzheimer\u2019s disease brain, blood, and cerebrospinal fluid.","volume":"15","author":"Takousis","year":"2019","journal-title":"Alzheimers Dement"},{"key":"R45-20250716","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.7150\/thno.47408","article-title":"Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer\u2019s disease by enhancing autophagy.","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"R46-20250716","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12974-022-02548-1","article-title":"MicroRNA-22-3p ameliorates Alzheimer\u2019s disease by targeting SOX9 through the NF-kappaB signaling pathway in the hippocampus.","volume":"19","author":"Xia","year":"2022","journal-title":"J Neuroinflammation"},{"key":"R47-20250716","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1093\/cercor\/bhab515","article-title":"miRNA-126a-3p participates in hippocampal memory via Alzheimer\u2019s disease-related proteins.","volume":"32","author":"Xue","year":"2022","journal-title":"Cereb Cortex"},{"key":"R48-20250716","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1007\/s12035-019-1500-y","article-title":"Systematic review of miRNA as biomarkers in Alzheimer\u2019s disease.","volume":"56","author":"Swarbrick","year":"2019","journal-title":"Mol Neurobiol"},{"key":"R49-20250716","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fncel.2014.00075","article-title":"Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders.","volume":"8","author":"Maffioletti","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"R50-20250716","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/nu9090927","article-title":"Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer\u2019s disease.","volume":"9","author":"Kou","year":"2017","journal-title":"Nutrients"},{"key":"R51-20250716","first-page":"702","article-title":"[Beta amyloid hypothesis in Alzheimer\u2019s disease: pathogenesis, prevention, and management].","volume":"41","author":"Zhang","year":"2019","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"R52-20250716","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"R53-20250716","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"R54-20250716","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1038\/s41380-020-0842-1","article-title":"Blood cell-produced amyloid-beta induces cerebral Alzheimer-type pathologies and behavioral deficits.","volume":"26","author":"Sun","year":"2021","journal-title":"Mol Psychiatry"},{"key":"R55-20250716","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","article-title":"CNS tau efflux via exosomes is likely increased in Parkinson\u2019s disease but not in Alzheimer\u2019s disease.","volume":"12","author":"Shi","year":"2016","journal-title":"Alzheimers Dement"},{"key":"R56-20250716","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/1567205018666210324122840","article-title":"Effects of gene and plasma tau on cognitive impairment in rural Chinese population.","volume":"18","author":"Tang","year":"2021","journal-title":"Curr Alzheimer Res"},{"key":"R57-20250716","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials.","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"R58-20250716","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41398-020-0801-2","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment.","volume":"10","author":"Liu","year":"2020","journal-title":"Transl Psychiatry"},{"key":"R59-20250716","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/alz.12166","article-title":"Blood neuro-exosomal synaptic proteins predict Alzheimer\u2019s disease at the asymptomatic stage.","volume":"17","author":"Jia","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R60-20250716","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.bbadis.2016.06.001","article-title":"Are circulating microRNAs peripheral biomarkers for Alzheimer\u2019s disease?","volume":"1862","author":"Kumar","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"R61-20250716","doi-asserted-by":"crossref","first-page":"2638130","DOI":"10.1155\/2020\/2638130","article-title":"RNA and oxidative stress in Alzheimer\u2019s disease: focus on microRNAs.","volume":"2020","author":"Nunomura","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"R62-20250716","doi-asserted-by":"crossref","first-page":"101497","DOI":"10.1016\/j.arr.2021.101497","article-title":"Identification of altered exosomal microRNAs and mRNAs in Alzheimer\u2019s disease.","volume":"73","author":"Su","year":"2022","journal-title":"Ageing Res Rev"},{"key":"R63-20250716","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/0122115366243970230925061819","article-title":"miRNA as an ultimate and emerging diagnostic approach for the detection of Alzheimer\u2019s disease.","volume":"12","author":"Jain","year":"2023","journal-title":"Microrna"},{"key":"R64-20250716","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease.","volume":"18","author":"Khan","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"R65-20250716","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","article-title":"Neuro-inflammation and anti-inflammatory treatment options for Alzheimer\u2019s disease.","volume":"72","author":"Ozben","year":"2019","journal-title":"Clin Biochem"},{"key":"R66-20250716","doi-asserted-by":"crossref","first-page":"116899","DOI":"10.1016\/j.biopha.2024.116899","article-title":"MicroRNA (miRNA) as a biomarker for diagnosis, prognosis, and therapeutics molecules in neurodegenerative disease.","volume":"177","author":"Alkhazaali-Ali","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R67-20250716","doi-asserted-by":"crossref","first-page":"107570","DOI":"10.1016\/j.cmpb.2023.107570","article-title":"Non-invasive detection of total bilirubin based on multi-wavelength PPG signal.","volume":"236","author":"Cheng","year":"2023","journal-title":"Comput Methods Programs Biomed"},{"key":"R68-20250716","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pedneo.2021.05.028","article-title":"Evaluation of the accuracy of a non-invasive hemoglobin-monitoring device in schoolchildren.","volume":"63","author":"Okazaki","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"R69-20250716","first-page":"1","article-title":"The impact of the pneumatic logistics transmission system + intelligent robot on blood routine and coagulation function test outcomes.","volume":"6","author":"Zhang","year":"2024","journal-title":"Altern Ther Health Med"},{"key":"R70-20250716","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer\u2019s disease in the era of biomarkers.","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"key":"R71-20250716","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.3390\/ijms25115970","article-title":"Epigenetics in Alzheimer\u2019s disease: a critical overview.","volume":"25","author":"Villa","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T23:01:36Z","timestamp":1752706896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":71,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038978","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}